Hapit, excellent focus on overlooked gems in the conference call. This approach is right out of the Gottlieb/Woodcock playbook for precision medicine and will be the modus operandi as Gottlieb builds his CNS Center of Excellence within the FDA.
One other point not investigated by this board is that while CM is getting more than his share of slings and arrows deserved or not for his management style (uniquely Bavarian), what is his staff, the BOD and SAB doing behind the curtain? Grant me some educated guesses.
1. Drs Missling , Fadiran and Klamer are handling the fast changing FDA and AUS regulative environment for trial submissions in the US and Australia. They are also working in close liaison with foundations,(RSF, MJFF, FRAXA, FAST, West Syndrome Foundations and others).
2. Tom Skarpelos, Dr Donhauser and Dr Klamer, are working the European theater arranging for the PK trial sponsor and liaising with the EMA as its in the middle of the move from London to Brussels.
3. Dr Thomas is in contact with his former employer, Takeda, seeing what their forward plans are after the Shire buyout and what broader Asian partnership opportunities are possible.
4. Elliot Favas and our new business VPs,, Stephan Toutain and Claus van der Velden are working partnership and out licensing possibilities with who knows how many pharma entities and managing the company's financial health to include grants and Federal assistance (NIH and ACTC).
5. The SAB is meanwhile working the Sigma-1 research and development area seeking opportunities for further research in a broad spectrum of neurodegenerative diseases.
So IMHO Chris Missling's brief and guarded conversations with us are Germanic consevatism which belies a great deal of activity within ANAVEX.
Market Data 
Markets 
AI
